➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Dow
Harvard Business School
McKinsey
Boehringer Ingelheim

Last Updated: March 2, 2021

DrugPatentWatch Database Preview

Oxprenolol hydrochloride - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for oxprenolol hydrochloride and what is the scope of patent protection?

Oxprenolol hydrochloride is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for oxprenolol hydrochloride.

Summary for oxprenolol hydrochloride
US Patents:0
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 1
Bulk Api Vendors: 60
Patent Applications: 659
DailyMed Link:oxprenolol hydrochloride at DailyMed

US Patents and Regulatory Information for oxprenolol hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis TRASICOR oxprenolol hydrochloride CAPSULE;ORAL 018166-004 Dec 28, 1983 DISCN No No   Start Trial   Start Trial   Start Trial
Novartis TRASICOR oxprenolol hydrochloride CAPSULE;ORAL 018166-001 Dec 28, 1983 DISCN No No   Start Trial   Start Trial   Start Trial
Novartis TRASICOR oxprenolol hydrochloride CAPSULE;ORAL 018166-002 Dec 28, 1983 DISCN No No   Start Trial   Start Trial   Start Trial
Novartis TRASICOR oxprenolol hydrochloride CAPSULE;ORAL 018166-003 Dec 28, 1983 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for oxprenolol hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis TRASICOR oxprenolol hydrochloride CAPSULE;ORAL 018166-002 Dec 28, 1983   Start Trial   Start Trial
Novartis TRASICOR oxprenolol hydrochloride CAPSULE;ORAL 018166-003 Dec 28, 1983   Start Trial   Start Trial
Novartis TRASICOR oxprenolol hydrochloride CAPSULE;ORAL 018166-004 Dec 28, 1983   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Colorcon
AstraZeneca
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.